OncoCyte (NASDAQ:OCX) Given New $4.25 Price Target at Needham & Company LLC

OncoCyte (NASDAQ:OCX) had its price objective increased by Needham & Company LLC from $3.60 to $4.25 in a report published on Wednesday morning, Benzinga reports. They currently have a buy rating on the stock.

OCX has been the subject of a number of other reports. Stephens reiterated an equal weight rating and set a $4.00 target price on shares of OncoCyte in a report on Wednesday, April 17th. Benchmark reiterated a speculative buy rating and issued a $5.00 price objective on shares of OncoCyte in a report on Monday, April 15th. Finally, StockNews.com initiated coverage on OncoCyte in a research report on Wednesday. They issued a sell rating on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, OncoCyte has an average rating of Hold and a consensus target price of $4.06.

OncoCyte Stock Performance

Shares of OncoCyte stock opened at $2.46 on Wednesday. OncoCyte has a 52-week low of $2.08 and a 52-week high of $6.20. The company’s 50 day moving average price is $2.92 and its 200-day moving average price is $3.04.

Insider Buying and Selling at OncoCyte

In other news, major shareholder Broadwood Partners, L.P. bought 2,420,000 shares of the firm’s stock in a transaction dated Thursday, April 11th. The stock was purchased at an average price of $2.92 per share, with a total value of $7,066,400.00. Following the transaction, the insider now owns 4,929,066 shares of the company’s stock, valued at $14,392,872.72. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other OncoCyte news, Director Andrew Arno acquired 33,898 shares of the business’s stock in a transaction on Thursday, April 11th. The shares were acquired at an average price of $2.95 per share, for a total transaction of $99,999.10. Following the completion of the acquisition, the director now owns 69,054 shares in the company, valued at $203,709.30. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Broadwood Partners, L.P. bought 2,420,000 shares of the stock in a transaction dated Thursday, April 11th. The shares were acquired at an average price of $2.92 per share, with a total value of $7,066,400.00. Following the completion of the acquisition, the insider now directly owns 4,929,066 shares of the company’s stock, valued at approximately $14,392,872.72. The disclosure for this purchase can be found here. In the last three months, insiders have bought 2,457,288 shares of company stock valued at $7,176,400. 1.94% of the stock is currently owned by corporate insiders.

About OncoCyte

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.